Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia
Abstract Background We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 16...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis 2011-01, Vol.214 (1), p.144-147 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 147 |
|---|---|
| container_issue | 1 |
| container_start_page | 144 |
| container_title | Atherosclerosis |
| container_volume | 214 |
| creator | Koh, Kwang Kon Quon, Michael J Lim, Soo Lee, Yonghee Sakuma, Ichiro Lee, Youn Hee Han, Seung Hwan Shin, Eak Kyun |
| description | Abstract Background We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% ( P = 0.014) and hsCRP from 1.10 to 0.90 mg/l ( P = 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% ( P = 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P = 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% ( P = 0.022) and 10 ± 3% ( P = 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels ( r = 0.279, P = 0.043) or leptin ( r = −0.280, P = 0.042). Conclusions Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients. |
| doi_str_mv | 10.1016/j.atherosclerosis.2010.10.023 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_835117044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915010008774</els_id><sourcerecordid>835117044</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-97e2e016ee20ccca9bb21d5c48737f5012e3b7ad1e64241d8a31dafa05a5fb303</originalsourceid><addsrcrecordid>eNqNkkFv1DAQhS0EokvhL4AvFacsHttZJweQqqoUpEocSs-W44x3nWbjYGdB-fc43aWHnrjYh_nmzfMbE3IBbA0MNp-6tZl2GEOy_XL6tObssbZmXLwgK6hUXYCs5EuyYoxDUUPJzsiblDrGmFRQvSZnHJgqhRIr0l07h3ZKNDjqcAjON9FMSJcZZpxpGKj10R56M_lhS03rx2DnKTz4ARP1Ax1zAYcs8MdPOzpGvzdxprt5xDhFv-1ni9G3uPfmLXnlTJ_w3ek-J_dfr39efStuf9x8v7q8Lays1VTUCjnmlyJyZq01ddNwaEsrKyWUKxlwFI0yLeBGcgltZQS0xhlWmtI1golz8vGoO8bw64Bp0nufLPa9GTAckq5ECaCYlJn8fCRtTjJFdPrkXwPTS9q608_S1kvaSzmnnfvfnyYdmj22T93_4s3AxQkwyZreRTPYrPHEiQo2tagz9-HIORO02cbM3N_lSeXjymrYZOLmSGBO7rfHqJPNuVtsfcz7023w_236yzMl2_vBZ3sPOGPqwiEOeT0adOKa6bvlEy1_CLKXSikp_gIZ8sin</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>835117044</pqid></control><display><type>article</type><title>Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Koh, Kwang Kon ; Quon, Michael J ; Lim, Soo ; Lee, Yonghee ; Sakuma, Ichiro ; Lee, Youn Hee ; Han, Seung Hwan ; Shin, Eak Kyun</creator><creatorcontrib>Koh, Kwang Kon ; Quon, Michael J ; Lim, Soo ; Lee, Yonghee ; Sakuma, Ichiro ; Lee, Youn Hee ; Han, Seung Hwan ; Shin, Eak Kyun</creatorcontrib><description>Abstract Background We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% ( P = 0.014) and hsCRP from 1.10 to 0.90 mg/l ( P = 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% ( P = 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P = 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% ( P = 0.022) and 10 ± 3% ( P = 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels ( r = 0.279, P = 0.043) or leptin ( r = −0.280, P = 0.042). Conclusions Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.</description><identifier>ISSN: 0021-9150</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2010.10.023</identifier><identifier>PMID: 21075373</identifier><language>eng</language><publisher>Amsterdam: Elsevier Ireland Ltd</publisher><subject>Adipocytokines ; Adipokines - blood ; Adipokines - metabolism ; adiponectin ; atherosclerosis ; Atherosclerosis (general aspects, experimental research) ; Biological and medical sciences ; biomarkers ; Biomarkers - metabolism ; Blood and lymphatic vessels ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiology. Vascular system ; Cardiovascular ; Cross-Over Studies ; Endothelial function ; Female ; Fenofibrate ; Fenofibrate - therapeutic use ; Hemoglobins - metabolism ; Humans ; Hypertriglyceridemia ; Hypertriglyceridemia - blood ; Hypertriglyceridemia - metabolism ; Hypolipidemic Agents - pharmacology ; Inflammation ; Insulin Resistance ; leptin ; Male ; Medical sciences ; Middle Aged ; patients ; Pharmacology. Drug treatments ; Placebos ; resistin ; therapeutics ; tumor necrosis factor-alpha ; Tumor Necrosis Factor-alpha - metabolism</subject><ispartof>Atherosclerosis, 2011-01, Vol.214 (1), p.144-147</ispartof><rights>Elsevier Ireland Ltd</rights><rights>2010 Elsevier Ireland Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-97e2e016ee20ccca9bb21d5c48737f5012e3b7ad1e64241d8a31dafa05a5fb303</citedby><cites>FETCH-LOGICAL-c497t-97e2e016ee20ccca9bb21d5c48737f5012e3b7ad1e64241d8a31dafa05a5fb303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0021915010008774$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23816939$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21075373$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koh, Kwang Kon</creatorcontrib><creatorcontrib>Quon, Michael J</creatorcontrib><creatorcontrib>Lim, Soo</creatorcontrib><creatorcontrib>Lee, Yonghee</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Lee, Youn Hee</creatorcontrib><creatorcontrib>Han, Seung Hwan</creatorcontrib><creatorcontrib>Shin, Eak Kyun</creatorcontrib><title>Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>Abstract Background We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% ( P = 0.014) and hsCRP from 1.10 to 0.90 mg/l ( P = 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% ( P = 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P = 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% ( P = 0.022) and 10 ± 3% ( P = 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels ( r = 0.279, P = 0.043) or leptin ( r = −0.280, P = 0.042). Conclusions Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.</description><subject>Adipocytokines</subject><subject>Adipokines - blood</subject><subject>Adipokines - metabolism</subject><subject>adiponectin</subject><subject>atherosclerosis</subject><subject>Atherosclerosis (general aspects, experimental research)</subject><subject>Biological and medical sciences</subject><subject>biomarkers</subject><subject>Biomarkers - metabolism</subject><subject>Blood and lymphatic vessels</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular</subject><subject>Cross-Over Studies</subject><subject>Endothelial function</subject><subject>Female</subject><subject>Fenofibrate</subject><subject>Fenofibrate - therapeutic use</subject><subject>Hemoglobins - metabolism</subject><subject>Humans</subject><subject>Hypertriglyceridemia</subject><subject>Hypertriglyceridemia - blood</subject><subject>Hypertriglyceridemia - metabolism</subject><subject>Hypolipidemic Agents - pharmacology</subject><subject>Inflammation</subject><subject>Insulin Resistance</subject><subject>leptin</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>resistin</subject><subject>therapeutics</subject><subject>tumor necrosis factor-alpha</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><issn>0021-9150</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkkFv1DAQhS0EokvhL4AvFacsHttZJweQqqoUpEocSs-W44x3nWbjYGdB-fc43aWHnrjYh_nmzfMbE3IBbA0MNp-6tZl2GEOy_XL6tObssbZmXLwgK6hUXYCs5EuyYoxDUUPJzsiblDrGmFRQvSZnHJgqhRIr0l07h3ZKNDjqcAjON9FMSJcZZpxpGKj10R56M_lhS03rx2DnKTz4ARP1Ax1zAYcs8MdPOzpGvzdxprt5xDhFv-1ni9G3uPfmLXnlTJ_w3ek-J_dfr39efStuf9x8v7q8Lays1VTUCjnmlyJyZq01ddNwaEsrKyWUKxlwFI0yLeBGcgltZQS0xhlWmtI1golz8vGoO8bw64Bp0nufLPa9GTAckq5ECaCYlJn8fCRtTjJFdPrkXwPTS9q608_S1kvaSzmnnfvfnyYdmj22T93_4s3AxQkwyZreRTPYrPHEiQo2tagz9-HIORO02cbM3N_lSeXjymrYZOLmSGBO7rfHqJPNuVtsfcz7023w_236yzMl2_vBZ3sPOGPqwiEOeT0adOKa6bvlEy1_CLKXSikp_gIZ8sin</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Koh, Kwang Kon</creator><creator>Quon, Michael J</creator><creator>Lim, Soo</creator><creator>Lee, Yonghee</creator><creator>Sakuma, Ichiro</creator><creator>Lee, Youn Hee</creator><creator>Han, Seung Hwan</creator><creator>Shin, Eak Kyun</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia</title><author>Koh, Kwang Kon ; Quon, Michael J ; Lim, Soo ; Lee, Yonghee ; Sakuma, Ichiro ; Lee, Youn Hee ; Han, Seung Hwan ; Shin, Eak Kyun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-97e2e016ee20ccca9bb21d5c48737f5012e3b7ad1e64241d8a31dafa05a5fb303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adipocytokines</topic><topic>Adipokines - blood</topic><topic>Adipokines - metabolism</topic><topic>adiponectin</topic><topic>atherosclerosis</topic><topic>Atherosclerosis (general aspects, experimental research)</topic><topic>Biological and medical sciences</topic><topic>biomarkers</topic><topic>Biomarkers - metabolism</topic><topic>Blood and lymphatic vessels</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular</topic><topic>Cross-Over Studies</topic><topic>Endothelial function</topic><topic>Female</topic><topic>Fenofibrate</topic><topic>Fenofibrate - therapeutic use</topic><topic>Hemoglobins - metabolism</topic><topic>Humans</topic><topic>Hypertriglyceridemia</topic><topic>Hypertriglyceridemia - blood</topic><topic>Hypertriglyceridemia - metabolism</topic><topic>Hypolipidemic Agents - pharmacology</topic><topic>Inflammation</topic><topic>Insulin Resistance</topic><topic>leptin</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>resistin</topic><topic>therapeutics</topic><topic>tumor necrosis factor-alpha</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koh, Kwang Kon</creatorcontrib><creatorcontrib>Quon, Michael J</creatorcontrib><creatorcontrib>Lim, Soo</creatorcontrib><creatorcontrib>Lee, Yonghee</creatorcontrib><creatorcontrib>Sakuma, Ichiro</creatorcontrib><creatorcontrib>Lee, Youn Hee</creatorcontrib><creatorcontrib>Han, Seung Hwan</creatorcontrib><creatorcontrib>Shin, Eak Kyun</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koh, Kwang Kon</au><au>Quon, Michael J</au><au>Lim, Soo</au><au>Lee, Yonghee</au><au>Sakuma, Ichiro</au><au>Lee, Youn Hee</au><au>Han, Seung Hwan</au><au>Shin, Eak Kyun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>214</volume><issue>1</issue><spage>144</spage><epage>147</epage><pages>144-147</pages><issn>0021-9150</issn><eissn>1879-1484</eissn><abstract>Abstract Background We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% ( P = 0.014) and hsCRP from 1.10 to 0.90 mg/l ( P = 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% ( P = 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P = 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% ( P = 0.022) and 10 ± 3% ( P = 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels ( r = 0.279, P = 0.043) or leptin ( r = −0.280, P = 0.042). Conclusions Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.</abstract><cop>Amsterdam</cop><pub>Elsevier Ireland Ltd</pub><pmid>21075373</pmid><doi>10.1016/j.atherosclerosis.2010.10.023</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9150 |
| ispartof | Atherosclerosis, 2011-01, Vol.214 (1), p.144-147 |
| issn | 0021-9150 1879-1484 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_835117044 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Adipocytokines Adipokines - blood Adipokines - metabolism adiponectin atherosclerosis Atherosclerosis (general aspects, experimental research) Biological and medical sciences biomarkers Biomarkers - metabolism Blood and lymphatic vessels Blood. Blood coagulation. Reticuloendothelial system Cardiology. Vascular system Cardiovascular Cross-Over Studies Endothelial function Female Fenofibrate Fenofibrate - therapeutic use Hemoglobins - metabolism Humans Hypertriglyceridemia Hypertriglyceridemia - blood Hypertriglyceridemia - metabolism Hypolipidemic Agents - pharmacology Inflammation Insulin Resistance leptin Male Medical sciences Middle Aged patients Pharmacology. Drug treatments Placebos resistin therapeutics tumor necrosis factor-alpha Tumor Necrosis Factor-alpha - metabolism |
| title | Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T18%3A24%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20fenofibrate%20therapy%20on%20circulating%20adipocytokines%20in%20patients%20with%20primary%20hypertriglyceridemia&rft.jtitle=Atherosclerosis&rft.au=Koh,%20Kwang%20Kon&rft.date=2011-01-01&rft.volume=214&rft.issue=1&rft.spage=144&rft.epage=147&rft.pages=144-147&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2010.10.023&rft_dat=%3Cproquest_cross%3E835117044%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=835117044&rft_id=info:pmid/21075373&rft_els_id=S0021915010008774&rfr_iscdi=true |